论文部分内容阅读
采用白蛋白修饰粉尘螨免疫治疗２９例尘螨过敏性哮喘息者，１９例未修饰粉尘螨浸液为对照组。结果治疗组临床改善优于对照组（Ｐ＜０．０５），治疗组鼻腔粘膜敏感性降低，特异性ＩｇＧ明显增高（Ｐ＜０．０１），对照组均无明显变化，嗜碱性粒细胞脱颗粒试验，两组治疗后均未见明显降低，治疗组特异性ＩｇＥ无明显改变，而对照组轻度升高。肝肾功能未见异常，无过敏反应发生。初步研究表明；白蛋白修饰粉尘螨可降低变应原性，并维持其免疫原性，是一种安全有效的变应原制剂。
29 cases of dust mite allergic asthma were treated with albumin modified dust mite immunotherapy, and 19 cases of unmodified dust mite drench as control group. Results The clinical improvement in the treatment group was better than that in the control group (P <0.05). The sensitivity of the nasal mucosa was decreased and the specific IgG was significantly increased in the treatment group (P <0.01), but no significant change was found in the control group. The basophils Degranulation test, no significant reduction in both groups after treatment, the treatment group specific IgE no significant change, while the control group was slightly elevated. No abnormal liver and kidney function, no allergic reaction. Preliminary studies have shown that albumin modified dust mites can reduce allergenicity and maintain its immunogenicity, is a safe and effective allergen preparation.